B25: Generation and Characterization of SARS-CoV-2 Spike Protein-Pseudotyped Lentivirus Particles for Use in Neutralizing Antibody Titer Testing of Human Serum by Sanchez, Luis
Generation and Characterization of SARS-CoV-2 Spike Protein-Pseudotyped Lentivirus Particles for Use in Neutralizing Antibody Titer Testing of Human Serum
• This research project was funded by the Touro University Nevada 2020 Mentored 
Student Research Award to Luis Sanchez and Karen M. Duus, Ph.D.
• GFP-expressing lentivirus backbone obtained from Dr. Carlos de Noronha laboratory, 
Albany Medical College, Albany, NY (2).
• ACE2-expressing HEK-293 cells and SARS-2 envelope expression construct obtained 
from the BEI reagent program at the National Institute of Health (NIH).
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• Co-transduction of A293T cells with a 1:1 or 1:2 ratio of SARS-2 S-protein 
expression vector to lentivirus backbone vector at 2.5ug total plasmid DNA 
yielded 34.8% and 34.3% transduction efficiencies, respectively. Following 
the same protocol, co-transduction with VSV-G envelope construct instead 
of SARS-2 S-protein expression vector resulted in 36.9% and 34.2% 
transduction efficiencies at 1:1 and 1:2 ratios, respectively (Figure 1, step 
2). There is no significant statistical difference between the transduction 
efficiencies between the SARS-2 and VSV-G pseudotyping protocol.
• In huACE-2 non-expressing HEK-293 cells incubated with the generated 
pseudotyped particles, GFP expression was observed in those infected 
with the VSV-G pseudotyped particles but not with the SARS-2 
pseudotyped particles (Figure 1, step 4a). 
• A total of 6 GFP-expressing cells identified between 3 of 9 HEK-293-ACE2 
cultures infected with a 100-fold dilution of SARS-2 pseudotyped virus 
aliquots (Figure 1, step 5)(Figure 3). At the same dilution of VSV-G 
pseudotyped virus aliquots, thousands of GFP expressing cells identified 
within 2 of 2 cultures.
• Western blot analysis of HEK 293-ACE2 cells confirms the presence of 
huACE2 receptor (Figure 2). This assay rules out the possibility that the 
absence of GFP expression in the HEK 293-ACE2 cells infected with the 
SARS-2 spike-pseudotyped virions was due to the absence of huACE2 
receptors.
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• Further research needs to be performed to identify solutions to 
successfully infect huACE2 positive cells with SARS-2 pseudotyped 
particles.
• Completion of this research will permit investigators to analyze antibody-
positive serum samples for neutralizing antibodies within BSL2 conditions. 
It may also assist future research that further investigates the level of 
neutralizing antibody protection induced by initial SARS-2 infections, how 
well these individuals may be protected against SARS-2 reinfection, and 
how long this protection may or may not last over time in subsequent 
serological studies. These are important questions that are currently being 
asked and have not been studied yet.
Figure 2. Image depicts Western Blot identifying the 
presence and absence of ACE2 receptor (126 kDa) in the 
HEK 293-ACE2 and HEK 293T parental cell lines 
respectively. Tubulin (47 kDa) used as a loading control.
Figure 1. Diagram depicts methods for production and characterization of SARS-2 pseudovirus particles.
1) Co-transfection of A293T cells with a GFP-expressing, envelope gene-deleted lentivirus backbone vector and with an 
epitope-tagged SARS-2 S-protein expressing vector (2)(4).
2) GFP expression of transfected A293T cells measured by fluorescence microscopy.
3) Pseudotyped particles harvested from co-transfection culture supernatant (48 hours), concentrated through 100kD 
centrifugal filter tubes and stored in small volume aliquots at -80C.  
4) Infection of HEK-293 cell lines with pseudotyped particles.
a) No SARS-2 pseudovirus infection in HEK-293 cell line.
b) SARS-2 pseudovirus infection expected in ACE2 expressing HEK-293 cell line.
5) GFP expression of infected HEK-293-ACE2 cells measured by fluorescence microscopy.
Generation of envelope and backbone constructs:
• SARS-2 envelope expression construct, VSV-G 
envelope construct, and envelope gene-deleted 
lentivirus backbone constructs generated from plasmid 
DNA expression vectors, amplified in transformed 
DH5α E. coli, isolated and purified on columns.
Production and characterization of SARS-2 
pseudovirus:
• Refer to Figure 1.
Production and characterization of control 
pseudovirus:
• Control pseudovirus particles generated by using the 
same co-transfection protocol but with a vesicular 
stomatitis virus (VSV) envelope G protein (VSV-G)-
expressing vector instead of the SARS-2 S-protein-
expressing vector.
Confirmation of ACE2 receptor on HEK cell lines:
• Refer to Figure 2. 
• SARS-CoV-2 (SARS-2) is a newly emerged pandemic 
coronavirus which causes COVID-19. 
• The extent to which those that recover from infection 
or are vaccinated are protected from subsequent 
infection by their adaptive immunity is not well 
understood. This protection comes from neutralizing 
antibodies which bind to spike proteins (S-protein) on 
the outside of virions, preventing its interaction with 
ACE-2 proteins on target cells. The virus is neutralized 
because the antibody prevents the virus from infecting 
the host cell, and this function can be measured in 
convalescent patient serum. 
• To date, it is not known how long these neutralizing 
antibodies remain in circulation at high enough titers to 
protect against infection months or years after infection 
or vaccination. Current COVID-19 serology tests are 
only able to determine if the individual tested has 
antibodies against the virus or not, but they do not 
reveal whether any of the antibodies are neutralizing 
antibodies (6).
• Pseudotyped viruses are often generated for use when 
using the wildtype infectious virus is considered too 
risky and when only one round of infection is required. 
• A pseudotyped virus involves generating chimeric virus 
particles in which the envelope protein of a virus (i.e., 
SARS-2 spike) is utilized on another viral backbone 
that is virtually harmless, because it is missing the 
gene for its own envelope protein. It is for this reason 
that pseudotyping has been utilized with viruses such 
as HIV (3), SARS-CoV-1 (5), and Ebola virus (1). 
The objective of this study is to generate SARS-2 
pseudotyped retrovirus particles expressing green 
fluorescent protein (GFP) when they infect target cells. 
The pseudotyped particles will enable us to measure anti-
S-protein neutralizing antibodies in human serum without 








Figure 2 Figure 3
Figure 3. Image depicts GFP expression in HEK-293-ACE2 
cells infected with SARS-2 pseudotyped particles at a 100-
fold dilution.
Background
